Drug
Lenvatinib
Lenvatinib: highest development phase Phase 3, developed by BeiGene, Eisai, Merck and others. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BeiGene, Eisai, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lenvatinib NCT04246177 | Phase 3 | Carcinoma, Hepatocellular |
| Lenvatinib NCT04401800 | Phase 2 | Hepatocellular Carcinoma |
| Lenvatinib NCT01136967 | Phase 2 | Unresectable Stage III |
| Lenvatinib NCT05171335 | Phase 2 | Hepatocellular Carcinoma |
| Lenvatinib NCT01137604 | Phase 2 | Glioma |
| Lenvatinib NCT05901194 | Phase 1/2 | Hepatocellular Carcinoma Non-resectable |
| Lenvatinib NCT02501096 | Phase 1/2 | Tumors |
| Lenvatinib NCT02421042 | Phase 1 | Hepatic Impairment |
| Lenvatinib NCT02792829 | Phase 1 | Healthy Volunteers |
| Lenvatinib NCT01525394 | Phase 1 | Refractory Solid Tumors |
Latest
No recent events.
Follow Lenvatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.